Novartis and Bristol Myers Squibb Suspend Autoimmune CAR-T Trials Following Patient Deaths
Here's what it means for you.
The suspension of these trials highlights the ongoing risks associated with innovative therapies, impacting future research and investment in the biotech sector.
What happened
Novartis halted eight clinical trials of its rap-cel CAR-T therapy after three patient deaths from severe immune reactions.
The Context
- Safety Concerns: The trials were paused due to fatal cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS), a known risk in CAR-T therapies.
- Broader Implications: Bristol Myers Squibb also paused its zola-cel program as a precaution, indicating a cautious approach in the industry towards autoimmune therapies.
- Regulatory Scrutiny: Ongoing safety reviews are being conducted with regulators and independent boards, emphasizing the need for rigorous oversight in clinical trials.
The Number
— This represents the patient deaths linked to severe immune reactions in Novartis's trials, underscoring the critical need for safety in experimental therapies.
Takeaway
As the industry navigates these challenges, expect increased scrutiny and potential delays in the development of autoimmune therapies.
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Drugmakers quietly halted autoimmune drug trials because of deaths or problematic side effects, raising questions about disclosure around experimental research
Drug manufacturers Novartis and Bristol Myers have halted trials for a promising autoimmune drug due to reports of deaths and problematic side effects, raising significant concerns about the safety and efficacy of the treatment. This decision has spa...
Tech business coverage, major deals, product launches, and Silicon Valley trends.
"WSJ’s tech section offers authoritative reporting on the intersection of technology and business, including exclusive industry analysis."
— A47 Editor
Drugmakers Halt Autoimmune Trials After Deaths, Life-Threatening Side Effects
Novartis and Bristol Myers have suspended their trials for a promising autoimmune treatment following reports of deaths and life-threatening side effects among participants. This decision has raised urgent questions about the safety and efficacy of t...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Swiss drugmaker Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders, after three patients died
Swiss drugmaker Novartis has paused eight clinical trials of an experimental therapy aimed at treating autoimmune and neurological disorders following the deaths of three patients. This decision was made in late August and raises significant concerns...
Health, medicine, wellness, and public health coverage with a UAE angle.
"Emirates 24|7 health coverage leans toward accessible reporting on healthcare updates, medical milestones, and wellness topics."
— A47 Editor
Novartis pauses autoimmune cell therapy studies after deaths
Novartis has paused eight clinical trials of an experimental therapy aimed at treating autoimmune and neurological disorders following the deaths of three patients due to severe immune responses. The company is conducting a comprehensive review of th...